MARKET COMPOSITE
PULM - Pulmatrix Inc6:00:17 PM 3/28/2024
Price
$1.69
+ 0.07 (4.32%)
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Financials
Quarterly financials
(USD)Jun 2023Q/Q
Revenue1.8MM+23%
Operating Income-4MM-13%
Operating Expenses5.8MM-4%
Net Income-3.8MM-14%
R&D4.2MM+8%
G&A1.7MM-24%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news